HTRA2 and metabolic dysfunction-associated steatotic liver disease: In summary, we reported that HtrA2/Omi expression could greatly reduce liver steatosis, improve glucose tolerance and hepatic insulin resistance in a mouse model of HFD-induced NAFLD.